Across disease types, FGFR1-4 SVs and REs were most commonly observed in bladder cancer (SVs: 1082/7739, 14.0%; REs: 220/7739, 2.8%), urinary tract cancer (SVs: 122/850, 14.4%; REs: 22/850, 2.6%), cholangiocarcinoma (SVs: 181/7729, 2.3%; REs: 668/7729, 8.6%), and endometrial cancers (SVs: 869/11 101, 7.8%; REs: 63/11 101, 0.6%); in bladder cancer, urinary tract cancer, and endometrial cancer, these were mostly SVs, whereas in cholangiocarcinoma, REs were the predominant FGFR genomic alteration (Figure 1). The gene discussed is FGFR1; the disease is urinary bladder carcinoma.